Events

A manuscript detailing this study is under revision and awaiting acceptance by the British Journal of Clinical Pharmacology.

When dealing with a cancer diagnosis, often times the best form of treatment can be offered through a clinical trial.

FDA's Amy Abernethy tells the Pink Sheet that initial priorities are likely to include studying COVID-19 natural history and how patients are faring under various medication regimens.

Today, we are announcing another step in our effort to harness diverse streams of data to understand and respond to COVID-19. The U.S.

The FDA said Tuesday it’s pairing up with the data company Aetion to research Covid-19 complications and what types of medicines virus patients are taking, which could help researchers learn more about which treatments are

The Food and Drug Administration said Tuesday that it will launch a new research project focused on real-world evidence — data collected by insurance companies, in electronic health records, and in other places in medicine

The COVID-19 crisis has fast-tracked long-contemplated, patient-centric changes in medicine.

Amy Abernethy, FDA’s principal deputy commissioner and acting CIO, and Mark McClellan, director of the Duke-Margolis Center for Health Policy at Duke University, described in podcast interviews with BioCentury’s Washington

The U.S. has been trying to contain COVID-19 through testing and social distancing. Now it’s time to kill it.

Life won’t completely return to normal while the novel coronavirus remains a threat to health and to life.